Solifenacin Production Cost Reports

The report provides a detailed analysis essential for establishing a Solifenacin production plant. It encompasses all critical aspects necessary for Solifenacin production, including the cost of Solifenacin production, Solifenacin plant cost, Solifenacin production costs, and the overall Solifenacin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Solifenacin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Solifenacin is a medication primarily used in the pharmaceutical industry for the treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO). Its industrial application is focused on producing this antimuscarinic drug, which helps reduce symptoms such as frequent urination, urgency, and urinary incontinence by acting on muscarinic receptors to relax bladder muscles and prevent spasms. It is widely prescribed and plays a key role in managing urinary conditions associated with bladder muscle overactivity.

The market for solifenacin is primarily driven by the increasing prevalence of overactive bladder (OAB) and urinary incontinence worldwide, fuelled by ageing populations and rising awareness and diagnosis of these conditions. The drug's effectiveness and the availability of both branded and generic formulations contribute to consistent market demand, mainly in regions such as North America, Europe, and emerging markets like Asia-Pacific.

The growing adoption of solifenacin in clinical settings, along with advancements in drug formulation and distribution channels, such as hospital pharmacies, retail pharmacies, and online platforms, further propels market growth. Additionally, the expanding research and development activities aimed at improving drug delivery and expanding indications also contribute to its demand. Moreover, fluctuations in active pharmaceutical ingredient (API) prices and production expenses, intensified by regulatory compliance, such as GMP standards and pharmacovigilance requirements, impact industrial solifenacin procurement. Additionally, the choice of formulation type, such as tablets being dominant, with oral solutions growing in niche segments, influences procurement based on demand from specific patient groups.

Raw Material for Solifenacin Production

According to the Solifenacin production plant project report, the various raw materials for Solifenacin production include 1,2,3,4-tetrahydro-1-phenylisoquinoline and ethyl chloroformate.

Production Process of Solifenacin

The extensive Solifenacin production cost report consists of the following major industrial production process:

1. Production via a multi-step process: The production process of Solifenacin involves a multi-step chemical process. The key steps include reacting 1,2,3,4-tetrahydro-1-phenylisoquinoline with ethyl chloroformate to produce an ester intermediate. This compound then reacts with quiniclidin-3-ol in the presence of sodium hydride, leading to the formation of Solifenacin through acylation.

Properties of Solifenacin

Solifenacin is a white to pale-yellowish-white crystalline powder with the molecular formula C23H26N2O2 and a molecular weight of 362.46 g/mol (for the base), while solifenacin succinate salt has a molecular weight of 480.55 g/mol. It has a melting point in the range of 134-136 degree Celsius. Solifenacin succinate is freely soluble in water, glacial acetic acid, dimethyl sulfoxide, and methanol.

It belongs to the muscarinic antagonist class with two chiral centres in its structure that contribute to its selective antagonism of the M3 muscarinic receptors. Solifenacin exhibits moderate lipophilicity with a logP around 3.9 and a pKa of 8.9. It exists as a solid with good bioavailability and is compliant with Lipinski's Rule of Five, indicating drug-likeness. Its polar surface area is around 33 Ų, and it contains multiple ring structures including quiniclidine and isoquinoline moieties, which are key to its pharmacological activity.